Updated
Reviewed by Chandani Patel
Europe Allergy Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Allergen, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$392.3 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $463.9 Mn | — | — |
| 2025 (base) | $495.0 Mn | +$31.1 Mn | — |
| 2026 (forecast) | $528.2 Mn | +$33.2 Mn | +6.7% |
| 2027 (forecast) | $563.6 Mn | +$35.4 Mn | +13.8% |
| 2028 (forecast) | $601.3 Mn | +$37.8 Mn | +21.5% |
| 2029 (forecast) | $641.6 Mn | +$40.3 Mn | +29.6% |
| 2030 (forecast) | $684.6 Mn | +$43.0 Mn | +38.3% |
| 2031 (forecast) | $730.5 Mn | +$45.9 Mn | +47.6% |
| 2032 (forecast) | $779.4 Mn | +$48.9 Mn | +57.5% |
| 2033 (forecast) | $831.6 Mn | +$52.2 Mn | +68% |
| 2034 (forecast) | $887.4 Mn | +$55.7 Mn | +79.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$1.04 Bn
China
$199.5 Mn
Canada
$162.4 Mn
Japan
$136.4 Mn
Germany
$74.3 Mn
France
$67.2 Mn
UK
$59.9 Mn
Italy
$53.2 Mn
Spain
$50.5 Mn
Brazil
$51.4 Mn
Ecuador
$50.0 Mn
Saudi Arabia
$47.2 Mn
India
$41.0 Mn
Mexico
$31.0 Mn
Australia
$28.9 Mn
Russia
$21.4 Mn
New Zealand
$21.1 Mn
South Africa
$14.5 Mn
UAE
$10.9 Mn
Egypt
$6.4 Mn
Philippines
$5.3 Mn
Malaysia
$3.7 Mn
Hong Kong
$3.6 Mn
Thailand
$3.2 Mn
Singapore
$2.6 Mn
Kenya
$1.8 Mn
| Market size, 2025 | $495.0 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $887.4 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 6.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, allergen and end user (see all) |
| Key players | ALK-Abello, Stallergenes Greer, HAL Allergy, Allergy Therapeutics, Aimmune (Nestle) (see all) |
| Regulator in Europe | EMASource: European Medicines Agency. Checked 14 Nov 2026. |
| Active clinical trials | 4 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Allergy immunotherapy gradually trains the immune system to tolerate allergens, using shots, tablets or drops.
Key segments of the allergy Immunotherapy market include type (Subcutaneous Immunotherapy, Sublingual Tablets and Sublingual Drops) and allergen (Pollen, Dust Mites and Food).
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the allergy Immunotherapy market. Biosimilars are widening access.
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the allergy Immunotherapy market room to grow.
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the allergy Immunotherapy market.
The allergy Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6] and MHRA (UK)[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[8] ClinicalTrials.gov lists 4 studies on Allergy Immunotherapy that are recruiting, active or about to start in Europe.[9]
[1] European Medicines Agency. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] European Commission, health technology assessment. Checked 14 Nov 2026.
[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allergy Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
What doctors and scientists are doing in Allergy Immunotherapy right now, from free public sources.
4 active trials in UK, Germany, France, Italy, Spain and Russia
Recruiting, about to start, or running now. Counted across the 6 countries we report on in Europe.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe
Europe
Europe
Europe
Europe
Europe
Medical Devices · Europe
Medical Devices · Europe
Healthcare Services · Europe
Healthcare Services · Europe
Medical Devices · Europe
Healthcare Services · Europe
Viatris
Teva Pharmaceutical